Sanofi and Regeneron Receive Positive CHMP Opinion for DupixentA to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis Sanofi and Regeneron Receive Positive CHMP Opinion for DupixentA to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis Paris, France and Tarrytown, N.Y. - July 21, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of DupixentA , recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
http://ift.tt/2gPIj7X
No comments:
Post a Comment